From a clinical perspective, of particular interest is our finding that subgroups of patients with intensely increased ACE2 expression levels exist in several cancer types, including NSCLC and breast cancers, as well as in glioblastoma and melanoma. The gene discussed is ACE2; the disease is breast cancer.